<?xml version="1.0" encoding="UTF-8"?>
<p>Long‐term management of SMO inhibitor‐related toxicities has been evaluated with visomdegib and sonidegib in patients with advanced basal cell carcinoma.
 <xref rid="ajh25238-bib-0056" ref-type="ref">56</xref>, 
 <xref rid="ajh25238-bib-0057" ref-type="ref">57</xref> The use of dose adjustments and interruptions to manage AEs have contributed to long treatment exposures and sustained clinical responses for these agents.
 <xref rid="ajh25238-bib-0056" ref-type="ref">56</xref>, 
 <xref rid="ajh25238-bib-0057" ref-type="ref">57</xref> Therefore, it will be critical to evaluate the long‐term safety of glasdegib and potentially apply similar strategies for AE management in patients with AML or high‐risk MDS.
</p>
